The Top 50 Big Pharma Partnering and M&A Deal Trends report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big pharma companies.

The Big pharma Deals and Alliances Review report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during the past year.

The Partnering Agreements with Pharmacyclics report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.

The Partnering Agreements with Jazz Pharmaceuticals report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.

The Partnering Agreements with Salix Pharmaceuticals report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.

The Partnering Agreements with Viropharma report provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies.

The Partnering Agreements with Vertex Pharmaceuticals report provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies.

The Partnering Agreements with Sun Pharmaceutical report provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies.

The Partnering Agreements with Spectrum Pharmaceuticals report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.

The Partnering Agreements with SciClone Pharmaceuticals report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.

Belgium-based healthcare company Omega Pharma NV is allegedly attracting numerous bids from businesses across the big pharma companies, according to Bloomberg Businessweek. Perrigo and Boehringer Ingelheim GmbH are rumored to be interested in acquiring the company.

UBS analyst Andrew Peters suggested that a recent takeover big in the biotech space of California-based InterMune, Inc.  by Roche was the harbinger of more M&A rumors to come.

The timing may be right for a takeover of Cubist Pharmaceuticals.

CP Insight > Insight Toolkit > Finding Partners > Making contact – with Big Pharma Making the right entry point into a bigpharma company is critical in ensuring your information does not end up going into a black hole. Increasingly in recent years bigpharma has come to realize the importance of partnering to the development of a robust product pipeline. As a more »

Big pharma or bigpharma is the collective name given to the top pharmaceutical companies in the world ranked…

Turmoil continues at big pharma, Teva Pharmaceutical Industries, which this week tried to dispel a report of company expectations of a dramatic decline in profit for its best-selling drug, and last week was suggested to be a possible takeover target by other drugmakers.

BioMarin Pharmaceutical Inc. (BMRN) may be up for acquisition because after  three years its most promising rare-disease drug came one step closer to U.S. regulatory approval this week.

Partnering trends and deal analysis reviewed with over 4,000 deals entered by the world’s leading fifty big pharma and big biotech companies

GlaxoSmithKline, a big pharma company, is discussing pharma deals for the sale of its thrombosis drug brands Arixtra and Fraxiparine, along with a related French factory, to Aspen Pharmacare in a deal that could be worth some $1 billion.

Acquisition rumours fly as GlaxoSmithKline, Astellas Cubist and AstraZeneca said to be interested in Optimer Pharmaceuticals takeover

Leidos was awarded a pharma deal with prime contract by the U.S. Defense Threat Reduction Agency to conduct research and development to combat weapons of mass destruction.

Catalent Pharma Solutions announced an agreement with the Center for iPS Cell Research and Application at Kyoto University in Japan to make a major advancement toward one of the first regenerative human therapies with induced pluripotent stem (iPS) cells applicable to humans.

Definiens and Metamark Genetics announced a multi-year agreement covering use of the Definiens image analysis solution for the ProMark.

Attendance is limited to 75 participants to ensure the optimal instructor/student ratio and quality interaction.

Merck KGaA agreed to acquire Sigma-Aldrich for $17 billion in cash to expand in chemicals used in research labs and pharmaceutical manufacturing and reduce its dependence on drug development.

Big pharma,  Pfizer Foundation announced $2 million in grant funding for pilot programs to improve immunization coverage in Africa.

Big pharma Bayer will spin off its plastics unit as the company moves further toward focusing solely on the life sciences market.

Big pharma, Merck Serono announced the establishment of a long-term strategic partnership with Lupin Limited.

BioHealth Innovation announced that big pharma, Roche entered into an agreement to advance healthcare technologies coming from academic institutions, federal laboratories and startups based in Central Maryland.

Big pharma company AstraZeneca announced an agreement with its U.S. peer Eli Lilly and Co. to jointly develop and commercialise BACE Inhibitor AZD3293, which is currently in development as a potential treatment for Alzheimer’s disease.

E-health company Trialbee signs professional service agreement with big pharma. AstraZeneca for e-recruitment.

Big pharma Eisai has entered into an agreement with Concordia Pharmaceuticals to purchase Eisai’s U.S. and Puerto Rican commercialization and distribution rights to Zonegran.

Cancer Research UK and Cancer Research Technology are to join forces with big pharma, Astellas Pharma to find new drug targets in the fight against cancer, with an initial focus on pancreatic cancer.

Big pharma, Bayer announced a $100,000 donation to the American Red Cross to support the organization’s national disaster and emergency preparedness efforts across the United States.